Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics

Main Article Content

Diana Betancor
Sara Bautista
Raquel López-Rodríguez
Marcela Valverde-Monge
Mar Fernández-Nieto
Manuel J. Rial https://orcid.org/0000-0003-4706-6608

Keywords

biologics, real-world-evidence, severe asthma, Tezepelumab, TSLP

Abstract

To evaluate the response to Tezepelumab in real clinical practice, we performed an analysis of the clinical, functional, and inflammatory characteristics of 13 patients with severe asthma after completing four doses of Tezepelumab was performed. When comparing clinical parameters such as asthma control test (ACT), FENO value, exacerbations in the last 4 months, blood eosinophils and FEV1%, before receiving Tezepelumab and after four doses of Tezepelumab, statistically significant differences were found in ACT levels (p=0.0072), exacerbations (p=0.018) and FEV1% (p=0.012) before and after four doses of Tezepelumab. No statistically significant differences were found in blood eosinophils or FeNO levels, however, a mean reduction of 102.5±231 cells/mm3 and 14.67±30 ppb, respectively, was observed. Patients with a high T2 profile had significantly higher baseline FeNO (p<0.05), but no significant improvement in lung function or asthma control was observed in this group. Patients with Aspirin-exacerbated respiratory disease (AERD) were evaluated separately. There was no difference in ACT, FeNO, or lung function changes after tezepelumab use compared to patients without AERD (all p>0.05). We demonstrated, in a multicenter study, the clinical improvement associated with tezepelumab treatment in severe uncontrolled asthma, independent of inflammatory biomarkers, eosinophilic profile, or previous biological failure.

Abstract 295 | PDF Downloads 425 HTML Downloads 0 XML Downloads 18

References

1 Ackman H, Jansson S, Stridsman C, et al. Severe asthma–a population study perspective. Clin Exp Allergy. 2019; 49: 819–828. 10.1111/cea.13378

2 Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. 10.3389/fped.2019.00246

3 Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23(1):24–37. 10.1016/j.coi.2010.10.020

4 Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–9. 10.1056/NEJMoa2034975

5 McDowell PJ, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker S, et al. Exacerbation profile and risk factors in a type-2-low enriched severe asthma cohort: a clinical trial to assess asthma exacerbation phenotypes. Am J Respir Crit Care Med. 2022 Sep 1;206(5):545–553. 10.1164/rccm.202201-0129OC.

6 Biener L, Mümmler C, Hinze CA, Suhling H, Korn S, Fisser C, et al. Real-world data on tezepelumab in patients with severe asthma in Germany. J Allergy Clin Immunol Pract. 2024 Sep;12(9):2399–2407.e5. 10.1016/j.jaip.2024.05.052

7 Violán VV, Cano BG, Casero MÁR, González-Mancebo E, Vicente EM, Trujillo MJT, et al. Real-life experience after 3 months with tezepelumab before marketing approval. Allergol Immunopathol. 2024;1;52(2):80–82. 10.15586/aei.v52i2.1063

8 Jiménez-Gómez M, Díaz-Campos RM, Gimeno-Díaz-De-Atauri Á, Fernández-Rodríguez C, Fernández-Crespo J, García-Moguel I. Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study. J Asthma. 2024;9:1–4. 10.1080/02770903.2024.2349605

9 Principe S, Porsbjerg C, Bolm Ditlev S, Kjaersgaard Klein D, Golebski K, Dyhre-Petersen N, et al. Treating severe asthma: Targeting the IL-5 pathway. Clin Exp Allergy. 2021;51(8):992–1005. 10.1111/cea.13885